Tevogen Bio Holdings Inc. (TVGN)
- Previous Close
0.9845 - Open
1.4300 - Bid 0.9998 x 100
- Ask 1.4000 x 200
- Day's Range
0.9840 - 1.4800 - 52 Week Range
0.8030 - 21.0900 - Volume
20,849,172 - Avg. Volume
586,706 - Market Cap (intraday)
164.614M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
tevogen.comRecent News: TVGN
Performance Overview: TVGN
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TVGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TVGN
Valuation Measures
Market Cap
162.06M
Enterprise Value
163.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.46%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-60.48M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.52M
Research Analysis: TVGN
Company Insights: TVGN
TVGN does not have Company Insights